A population-based study of over 106903 individuals by Wu et al. also inferred that SGLT2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk of dementia (adjusted hazard ratio (aHR): 0.80; CI: 0.71-0.89) over a mean follow-up of 2.80 years [6]. The gene discussed is SLC5A2; the disease is dementia.